BioMark Diagnostics Inc.
BUX
CNSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -1.31% | 20.00% | -155.77% | -46.09% | 21.74% |
| Total Depreciation and Amortization | 111.36% | -42.58% | -36.89% | -44.84% | -1.58% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 332.84% | -8.94% | 173.76% | 337.80% | -88.91% |
| Change in Net Operating Assets | -518.31% | 123.76% | 264.79% | 8.04% | -52.58% |
| Cash from Operations | -97.93% | 63.57% | -988.64% | -26.09% | -22.76% |
| Capital Expenditure | 22.22% | 100.00% | 100.00% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 22.22% | 100.00% | 100.00% | -- | -- |
| Total Debt Issued | 0.00% | 23.52% | 0.00% | 0.00% | 0.00% |
| Total Debt Repaid | 54.20% | 70.89% | 53.50% | -21.22% | -97.76% |
| Issuance of Common Stock | 737.40% | -74.02% | -69.46% | -4.57% | 61.96% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 4,396.83% | -63.72% | 288.89% | -14.42% | -47.37% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,538.74% | -63.78% | -1,433.33% | -114.58% | -153.61% |